Jessica Cook1, Bonnie Spring, Dennis McChargue, Neal Doran. 1. Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, 1930 Monroe St., Suite 200, Madison, WI 53711, USA. jwcook@ctri.medicine.wisc.edu
Abstract
INTRODUCTION: Despite the strong co-occurrence between lifetime prevalence of depression and smoking, a history of major depressive disorder (MDD history) does not reliably predict smoking cessation outcomes. However, depression is a heterogeneous syndrome comprising several dimensions (e.g., anhedonia, vegetative symptoms, negative affect), and each symptom expression may differentially influence cessation failure. Measuring proximal depressive dimensions may provide a more reliable way of identifying MDD history smokers most at risk for smoking relapse. Anhedonia, in particular, is a core feature of depression that may increase risk for smoking relapse among MDD history smokers. The primary goal of the present study was to investigate the relation between anhedonia and relapse latency among MDD history smokers following a brief smoking cessation workshop. METHODS:Participants (N = 45, 48.9% female), who were euthymic regular smokers with a history of MDD, were randomized to 1 of 3 treatment groups that all involved participation in a daylong group workshop. Workshops were followed by 48 hr of bioverified abstinence and weekly follow-up visits for 1 month. RESULTS: Cox proportional hazard modeling was used to evaluate the effect of anhedonia on relapse latency 30 days following quitting smoking. Results showed that higher levels of anhedonia predicted reduced relapse latencies, both with and without prequit depressive symptom severity included in the model. DISCUSSION: Results suggest that anhedonia may constitute a proximal risk factor identifying depressive history smokers more likely to relapse to smoking.
RCT Entities:
INTRODUCTION: Despite the strong co-occurrence between lifetime prevalence of depression and smoking, a history of major depressive disorder (MDD history) does not reliably predict smoking cessation outcomes. However, depression is a heterogeneous syndrome comprising several dimensions (e.g., anhedonia, vegetative symptoms, negative affect), and each symptom expression may differentially influence cessation failure. Measuring proximal depressive dimensions may provide a more reliable way of identifying MDD history smokers most at risk for smoking relapse. Anhedonia, in particular, is a core feature of depression that may increase risk for smoking relapse among MDD history smokers. The primary goal of the present study was to investigate the relation between anhedonia and relapse latency among MDD history smokers following a brief smoking cessation workshop. METHODS:Participants (N = 45, 48.9% female), who were euthymic regular smokers with a history of MDD, were randomized to 1 of 3 treatment groups that all involved participation in a daylong group workshop. Workshops were followed by 48 hr of bioverified abstinence and weekly follow-up visits for 1 month. RESULTS: Cox proportional hazard modeling was used to evaluate the effect of anhedonia on relapse latency 30 days following quitting smoking. Results showed that higher levels of anhedonia predicted reduced relapse latencies, both with and without prequit depressive symptom severity included in the model. DISCUSSION: Results suggest that anhedonia may constitute a proximal risk factor identifying depressive history smokers more likely to relapse to smoking.
Authors: Julia D Buckner; Samantha G Farris; Michael J Zvolensky; Sonia M Shah; Adam M Leventhal; Jennifer A Minnix; Norman B Schmidt Journal: Am J Drug Alcohol Abuse Date: 2014-11-14 Impact factor: 3.829
Authors: Janet Audrain-McGovern; Daniel Rodriguez; Adam M Leventhal; Jocelyn Cuevas; Kelli Rodgers; Joseph Sass Journal: Nicotine Tob Res Date: 2012-03-01 Impact factor: 4.244
Authors: Christopher W Kahler; Nichea S Spillane; Anne Day; Elise Clerkin; Acacia Parks; Adam M Leventhal; Richard A Brown Journal: J Posit Psychol Date: 2014-01-01
Authors: Adam M Leventhal; Marcus Munafò; Jennifer W Tidey; Steve Sussman; John R Monterosso; Ping Sun; Christopher W Kahler Journal: Psychopharmacology (Berl) Date: 2012-02-04 Impact factor: 4.530
Authors: Gabrielle I Liverant; Denise M Sloan; Diego A Pizzagalli; Christopher B Harte; Barbara W Kamholz; Laina E Rosebrock; Andrew L Cohen; Maurizio Fava; Gary B Kaplan Journal: Behav Ther Date: 2014-02-13
Authors: F Scott Hall; Andre Der-Avakian; Thomas J Gould; Athina Markou; Mohammed Shoaib; Jared W Young Journal: Neurosci Biobehav Rev Date: 2015-06-06 Impact factor: 8.989